ABT — ABBOTT LABORATORIES

NYSE · Health Care · Pharmaceuticals · CIK 1800 ·
Last close
$110.91
Market Cap
$193.18B
52W High
$111.28
52W Low
$82.10
ADV30
11,284,439
Next earnings
2026-10-14
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026
Mar 2026 11,164,000,000 6,274,000,000 1,345,000,000 1,077,000,000 110,429,000,000 6,803,000,000 57,728,000,000
Dec 2025 11,459,000,000 6,537,000,000 2,251,000,000 1,776,000,000 86,713,000,000 8,522,000,000 33,942,000,000
Sep 2025 11,369,000,000 6,294,000,000 2,057,000,000 1,644,000,000 84,181,000,000 7,511,000,000 32,917,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$9,464,000,000
Investing CF
$-22,276,000,000
Financing CF
$13,059,000,000
CapEx
$-2,086,000,000
Dividends Paid
$-4,188,000,000
Buybacks
$-793,000,000
EPS Diluted TTM
$3.09
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$49,956,000,000
Inventory
$6,989,000,000
Receivables
$11,224,000,000
ST Investments
$492,000,000
EBIT TTM
$8,673,000,000
Pretax Income TTM
$8,137,000,000
Interest Exp TTM
$536,000,000
Analysts
24

Yahoo Snapshot (yfinance, live)

Total Revenue
$46,584,999,936
EBITDA
$11,681,000,448
Free Cash Flow
$7,209,124,864
Enterprise Value
$219,685,814,272
Total Cash
$5,602,999,808
Total Debt
$32,719,998,976
Shares Out
1,741,813,154
Trailing EPS
$3.13
Book Value
$29.54
ROE
10.6%
ROA
5.3%
Div Yield
2.30%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 44,328,000,000 8,053,000,000 6,524,000,000 86,713,000,000 33,942,000,000 9,566,000,000
Dec 2024 41,950,000,000 6,825,000,000 13,402,000,000 81,414,000,000 33,513,000,000 8,558,000,000
Dec 2023 40,109,000,000 6,478,000,000 5,723,000,000 73,214,000,000 34,387,000,000 7,261,000,000
Dec 2022 43,653,000,000 8,362,000,000 6,933,000,000 74,438,000,000 37,533,000,000 9,581,000,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$6.06

Max Pain — expiry 2026-08-21

max pain strike: $97.50 · spot: $111.03 · call oi: 32,812 · put oi: 17,732
Expected Move to 2026-08-21: ±$3.08 (2.77%) — implied range $107.95$114.10 · ATM straddle on $111.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NVO NOVO NORDISK A S $153.38B $46.39
AZN ASTRAZENECA PLC $245.82B $158.50
PFE PFIZER INC $149.96B $26.31
NONOF NOVO NORDISK A S $143.36B $43.36
VRTX VERTEX PHARMACEUTICALS INC / MA $133.17B $525.73

News headlines (Yahoo Finance, 1h cache)

What's Backing Abbott's Established Pharmaceuticals Division Growth
2026-08-13 12:49 · Yahoo
Abbott Laboratories (ABT) Ties Lingo Glucose Data To AI Health Tools
2026-08-12 21:13 · Yahoo
Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
2026-08-12 13:14 · Yahoo
Arrow Exploration confirms four zones at Icaco 3, opens up ~10 new drilling locations
2026-08-11 17:41 · Yahoo
Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?
2026-08-10 20:49 · Yahoo
Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle
2026-08-13 12:37 · Yahoo
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
2026-08-13 11:53 · Yahoo
[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Grow
2026-08-12 17:30 · Yahoo
The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists
2026-08-13 15:02 · Yahoo
Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?
2026-08-12 18:36 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.